枸橼酸艾沙佐米 T8397

Product Introduction
Bioactivity


英文名: Ixazomib citrate

描述: Ixazomib citrate (MLN9708) 是 Ixazomib 的前药，是20S 蛋白酶体胰凝乳蛋白酶样蛋白水解β5位点的可逆抑制剂，IC50为3.4 nM 和Ki 为0.93 nM。

体外活性: Treatment of MM cells with MLN2238 predominantly inhibits chymotrypsin-like activity of the proteasome and induces accumulation of ubiquitinated proteins. MLN2238 inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies without affecting the viability of normal cells[1].

体内活性: In animal tumor model studies, MLN2238 is well tolerated and inhibits tumor growth with significantly reduced tumor recurrence. A head-to-head analysis of MLN2238 versus bortezomib showed a significantly longer survival time in mice treated with MLN2238 than mice receiving bortezomib[1].

存储条件: keep away from direct sunlightPowder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 100 mg/mL (193.38 mM)


关键字: Proteasome | Ixazomib | Inhibitor | Ixazomib citrate | Autophagy | MLN 9708 | Ixazomib Citrate | MLN-9708 | inhibit

相关产品: LXE408 fumarate | Cilastatin | Teneligliptin hydrobromide | MDL-28170 | TCH-165 | Sitagliptin | Linagliptin Methyldimer | Gemigliptin Tartrate(911637-19-9 free base) | Oprozomib | Pepstatin

相关库: Drug Repurposing Compound Library | Targeted Therapy Drug Library | Anti-Cancer Drug Library | Clinical Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | EMA Approved Drug Library | Protease Inhibitor Library

枸橼酸艾沙佐米 T8397信息由TargetMol中国为您提供，如您想了解更多关于枸橼酸艾沙佐米 T8397报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途